A probiotic bioengineered by UBC Okanagan researchers to thrive in the inflamed gut is set to enter human clinical trials in Australia this summer, capping a decade-long effort to turn a beneficial bacterium into a treatment for inflammatory bowel disease.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗